Keyword: Stivarga

After Lilly’s Cyramza flopped a liver cancer trial in 2014, the company designed a trial for a specific subpopulation. Now, it’s back with a win.

Kidney cancer isn’t the only disease area where Merck’s Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo.

Bayer is working to position Stivarga as part of a liver cancer treatment regimen, But that’s not going to work in England. At least, not yet.

Since NICE took the reins of England’s Cancer Drugs Fund last year, several drugmakers have seen their meds get the boot. Not Bayer.

With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.

Bayer's Nexavar has had the first-line liver cancer space to itself for years, but Eisai is doing its best to change that.

In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.

Phase 1 of Bayer’s liver cancer plan is complete: Build a bridge between Stivarga and first-line blockbuster Nexavar.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer now, its future pharma growth could be in jeopardy.